Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The difference in development cohort and the validation cohort in terms of the demographic characteristics, laboratory valuesParametersTotalDevelopment cohortValidation cohortt/χ2 P-valueMale/female624/292435/206189/860.0660.797Age (year)61.31 ± 13.4061.13 ± 13.2161.75 ± 13.85− 0.6420.521Length of stay (day)25.66 ± 51.7720.39 ± 16.9721.39 ± 18.21− 0.7230.470Diabetes duration (month)43.18 ± 24.7744.78 ± 26.1439.98 ± 21.482.9200.004Hypertension [n(%)]566 (61.8)393 (61.3)173 (62.9)0.2080.648CKD [n(%)]364 (39.7)258 (40.2)106 (38.5)0.2330.629BMI (kg/m2)24.04 ± 3.7123.80 ± 3.8624.16 ± 4.24− 1.0630.288PP (mmHg)58.62 ± 18.3857.83 ± 18.3859.51 ± 17.70− 1.2730.203MAP (mmHg)95.79 ± 17.2495.64 ± 18.1796.90 ± 17.05− 0.9710.332WBC (×109/L)12.51 ± 7.6812.63 ± 8.1312.21 ± 6.520.7820.434Hb (g/L)104.06 ± 23.28104.56 ± 23.11102.90 ± 23.670.9340.350PLT (×109/L)191.55 ± 86.90189.51 ± 82.64196.32 ± 96.15− 1.0240.306Alb (g/L)32.27 ± 7.1632.20 ± 7.9431.96 ± 7.710.3930.69525(OH)D3 (nmol/L)57.23 ± 23.2957.36 ± 23.6556.92 ± 22.470.2650.791NT-proBNP (pg/mL)3632.98 ± 1851.394122.55 ± 1701.354017.90 ± 1422.010.8800.379FBG (mmol/L)8.39 ± 2.948.46 ± 3.498.22 ± 3.420.8340.405PBG (mmol/L)12.44 ± 2.8012.41 ± 3.9512.34 ± 4.150.1700.865HbA1c (%)7.52 ± 1.367.49 ± 1.627.48 ± 1.740.1020.918BUN (mmol/L)13.89 ± 8.8514.00 ± 9.9714.15 ± 10.28− 0.1940.846Baseline Scr (µmol/L)132.53 ± 102.00141.09 ± 116.94149.80 ± 139.41− 0.7980.425UA (µmol/L)422.60 ± 196.55418.43 ± 197.07410.48 ± 203.230.5400.589HCO3− (mmol/L)22.04 ± 5.2322.13 ± 5.1821.82 ± 5.360.8070.420Cystatin C (mg/L)2.31 ± 1.452.35 ± 1.492.24 ± 1.361.0110.312Serum potassium (mmol/L)4.19 ± 0.814.20 ± 0.814.17 ± 0.810.4920.623AKI stage3.0740.215 1402 (43.9)273 (42.6)129 (46.9) 2337 (36.8)235 (36.7)102 (37.1) 3177 (19.3)133 (20.7)44 (16.0)Discharged Scr (µmol/L)215.17 ± 160.55217.02 ± 160.71210.88 ± 160.380.5300.596RRT [n(%)]186 (20.3)140 (21.8)46 (16.7)3.1100.078Renal recovery304 (33.2)224 (34.9)80 (29.1)2.9750.08525(OH)D3 25-hydroxyvitamin D3; AKI acute kidney injury; Alb albumin; BMI body mass index; BUN blood urea nitrogen; CKD chronic kidney disease; FBG fasting blood glucose; Hb hemoglobin; HbA1c hemoglobin A1c; MAP mean arterial pressure; NT-proBNP N-terminal prohormone of brain natriuretic peptide; PBG postprandial blood glucose; PLT platelet count; PP pulse pressure; RRT renal replacement therapy; Scr Serum creatinine; UA uric acid; WBC white blood cell count
Source: Characteristics of patients in the development and validation cohorts. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Demographic data and related laboratory indicators of diabetic patients with AKI in the First Affiliated Hospital of Guangxi Medical University from January 31, 2012 to January 31, 2022 were retrospectively analysed, and patients were followed up to 90 days after AKI diagnosis.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Development and validation of short-term renal prognosis prediction model in diabetic patients with acute kidney injury
Study design awaiting verification · Diabetology & Metabolic Syndrome · 2022
Original publication title
Development and validation of short-term renal prognosis prediction model in diabetic patients with acute kidney injury
© The Author(s) 2022
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Diabetes is a major cause of the progression of acute kidney injury (AKI). Few prediction models have been developed to predict the renal prognosis in diabetic patients with AKI so far. The aim of this study was to develop and validate a predictive model to identify high-risk individuals with non-recovery of renal function at 90 days in diabetic patients with AKI.
Source: ObjectiveAbstract: What methods does the paper describe?
Demographic data and related laboratory indicators of diabetic patients with AKI in the First Affiliated Hospital of Guangxi Medical University from January 31, 2012 to January 31, 2022 were retrospectively analysed, and patients were followed up to 90 days after AKI diagnosis. Based on the results of Logistic regression, a model predicting the risk of non-recovery of renal function at 90 days in diabetic patients with AKI was developed and internal validated. Consistency index (C-index), calibration curve, and decision curve analysis were used to evaluate the differentiation, accuracy, and clinical utility of the prediction model, respectively.
Source: MethodsAbstract: Results
A total of 916 diabetic patients with AKI were enrolled, with a male to female ratio of 2.14:1. The rate of non-recovery of renal function at 90 days was 66.8% (612/916). There were 641 in development cohort and 275 in validation cohort (ration of 7:3). In the development cohort, a prediction model was developed based on the results of Logistic regression analysis. The variables included in the model were: diabetes duration (OR = 1.022, 95% CI 1.012 to 1.032), hypertension (OR = 1.574, 95% CI 1.043 to 2.377), chronic kidney disease (OR = 2.241, 95% CI 1.399 to 3.591), platelet (OR = 0.997, 95% CI 0.995 to 1.000), 25-hydroxyvitamin D3 (OR = 0.966, 95% CI 0.956 to 0.976), postprandial blood glucose (OR = 1.104, 95% CI 1.032 to 1.181), discharged serum creatinine (OR = 1.003, 95% CI 1.001 to 1.005).
The C-indices of the prediction model were 0.807 (95% CI 0.738 to 0.875) and 0.803 (95% CI 0.713 to 0.893) in the development and validation cohorts, respectively. The calibration curves were all close to the straight line with slope 1. The decision curve analysis showed that in a wide range of threshold probabilities.
Source: ResultsAbstract: Conclusion
A prediction model was developed to help predict short-term renal prognosis of diabetic patients with AKI, which has been verified to have good differentiation, calibration degree and clinical practicability.
Source: ConclusionAuthors’ abstract
Objective
Diabetes is a major cause of the progression of acute kidney injury (AKI). Few prediction models have been developed to predict the renal prognosis in diabetic patients with AKI so far. The aim of this study was to develop and validate a predictive model to identify high-risk individuals with non-recovery of renal function at 90 days in diabetic patients with AKI.
Methods
Demographic data and related laboratory indicators of diabetic patients with AKI in the First Affiliated Hospital of Guangxi Medical University from January 31, 2012 to January 31, 2022 were retrospectively analysed, and patients were followed up to 90 days after AKI diagnosis. Based on the results of Logistic regression, a model predicting the risk of non-recovery of renal function at 90 days in diabetic patients with AKI was developed and internal validated. Consistency index (C-index), calibration curve, and decision curve analysis were used to evaluate the differentiation, accuracy, and clinical utility of the prediction model, respectively.
Results
A total of 916 diabetic patients with AKI were enrolled, with a male to female ratio of 2.14:1. The rate of non-recovery of renal function at 90 days was 66.8% (612/916). There were 641 in development cohort and 275 in validation cohort (ration of 7:3). In the development cohort, a prediction model was developed based on the results of Logistic regression analysis. The variables included in the model were: diabetes duration (OR = 1.022, 95% CI 1.012 to 1.032), hypertension (OR = 1.574, 95% CI 1.043 to 2.377), chronic kidney disease (OR = 2.241, 95% CI 1.399 to 3.591), platelet (OR = 0.997, 95% CI 0.995 to 1.000), 25-hydroxyvitamin D3 (OR = 0.966, 95% CI 0.956 to 0.976), postprandial blood glucose (OR = 1.104, 95% CI 1.032 to 1.181), discharged serum creatinine (OR = 1.003, 95% CI 1.001 to 1.005).
The C-indices of the prediction model were 0.807 (95% CI 0.738 to 0.875) and 0.803 (95% CI 0.713 to 0.893) in the development and validation cohorts, respectively. The calibration curves were all close to the straight line with slope 1. The decision curve analysis showed that in a wide range of threshold probabilities.
Conclusion
A prediction model was developed to help predict short-term renal prognosis of diabetic patients with AKI, which has been verified to have good differentiation, calibration degree and clinical practicability.
Publication and source details
Original title: Development and validation of short-term renal prognosis prediction model in diabetic patients with acute kidney injury
Manqiu Mo; Zichun Huang; Tianyun Gao; Yuzhen Luo; Xiaojie Pan; Zhenhua Yang; Ning Xia; Yunhua Liao; Ling Pan
Diabetology & Metabolic Syndrome · 2022
© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.National Natural Science Foundation of China8176030057Xia Ning Guangxi Clinical Research Center for Urology and Nephrology2020AC03006Liao Yunhua Scientific Research and Technological Development Program of GuangxiGuiKeGong 1598011-6Liao Yunhua http://dx.doi.org/10.13039/501100004607Natural Science Foundation of Guangxi Province2018GXNSFBA050040Pan LingRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T08:19:19.862366+00:00
DOI: 10.1186/s13098-022-00971-1 · PMC9793591